Herzuma

The 1st subcutaneous formulation of infliximab • Ingredient: Infliximab  • Indication: Rheumatoid arthritis, inflammatory bowel disease • Mode of mechanism: Alleviate disease progression by inducing a neutralizing reaction to TNF-α, the cause of autoimmune disease • Approval status: 49 countries in...

The world's 1st mAb biosimilar • Ingredient: Infliximab • Indication: Rheumatoid arthritis, inflammatory bowel disease • Mode of mechanism: Relieves disease progression by inducing a neutralizing response to tumor necrosis factor(TNF-α), the cause of autoimmune disease • Approval status: 100 countri...

• Ingredient: Rituximab • Indication: Non-Hodgkin's lymphoma, rheumatoid arthritis • Mode of mechanism: Specifically binds to CD20, which is expressed on the cell surface of human B cells and lyses target cells to express pharmacological action with mechamisms such as complement-dependent cytotoxicity, ...

• Ingredient: Adalimumab • Indication: Rheumatoid arthritis, inflammatory bowel disease • Mode of mechanism: Blocks the transmission of inflammatory signals by binding to TNF-α in the body   • Approval status: 44 countries including the US(product name: Inflectra), Europe and South Korea 

Bora Pharmaceuticals, the international cGMP CDMO producing specialised pharmaceutical products such as sterile and non-sterile ophthalmics and nasal sprays for clinical use, is partnering with Celltrion Asia Pacific, subsidiary of Celltrion Group Inc.

brochure.celltrion.com

With new drug approvals hitting a record high in 2021 and unprecedented number of out-licensing deals closed in 2020, Korean pharmaceutical companies and CDMO’s are poised for significant market growth [i].